Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259867 · ClinicalTrials.gov registry record · Phase 2
Combination of TATE and PD-1 Inhibitor in Liver Cancer
A Phase 2 study of Gastric Cancer and Hepatocellular Carcinoma, sponsored by Teclison.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 3
- Study locations
NCT03259867 is a Phase 2 study of Gastric Cancer and Hepatocellular Carcinoma that is actively recruiting participants, run by Teclison. The registered enrollment target is 54 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT03259867, a Phase 2 study of Gastric Cancer and Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Teclison.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.
Conditions Studied
Interventions
- DRUG Nivolumab Injectable Product
- COMBINATION_PRODUCT Trans-arterial tirapazamine embolization
Study Locations (3)
California
- University of California, Irvine - Orange
Oklahoma
- University of Oklahoma Health Science Center - Oklahoma City
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03259867
The ClinicalTrials.gov registry entry for NCT03259867 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (83% lower). The listed sponsor is Teclison, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab Injectable Product is the first listed.
NCT03259867 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Oklahoma, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT03259867 about?
NCT03259867 is a clinical study titled "Combination of TATE and PD-1 Inhibitor in Liver Cancer". This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular...
What is the current status of trial NCT03259867?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2017-07-01. Estimated completion is 2025-12-31.
What conditions does trial NCT03259867 study?
This clinical trial studies the following conditions: Gastric Cancer, Hepatocellular Carcinoma.
What interventions are being tested in trial NCT03259867?
The interventions under investigation include: Nivolumab Injectable Product (DRUG), Trans-arterial tirapazamine embolization (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03259867?
This trial is sponsored by Teclison, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03259867 being conducted?
This trial has 3 study locations across California, Oklahoma, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
-
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.